Preliminary studies with the GRPR-antagonist-based [99mTc]Tc-DB15 (a Sar11-substituted analog of [99mTc]Tc-DB8) in two breast cancer (BCa) patients [29] and [99mTc]Tc-N4-BTG in four PCa patients with minimal biochemical recurrence [30] further confirmed the favorable pharmacokinetics conveyed by the trans-[99mTc][Tc(V)(O)2(N4)]+ radiometal–chelate. This evidence concerns the gene GRPR and posterior cortical atrophy.